Notably, treatment with 3 mg/kg of BAY-876, a GLUT1 inhibitor that mimics glucose starvation, produced similar anti-tumor effects, suggesting a potential link between CASC8 and glucose metabolism in vivo (P < 0.001). Here, SLC2A1 is linked to neoplasm.